Genetic Ophthalmology Disorders Drug Pipeline Examined by GBI Research in Its New Discounted Report Recently Added at MarketPublishers.com
24 Aug 2017 • by Natalie Aster
LONDON – Juvenile macular degeneration is a range of inherited eye disorders affecting children and/or young adults; the most common form is Stargardt disease (it is an inherited autosomal recessive syndrome). Leber congenital amaurosis firstly affects the retina, a specialised tissue at the back of eye, which detect color and light; it is the most common reason for inherited blindness in childhood. Leber’s hereditary optic neuropathy commonly begins in the age of teens or twenties, rare cases are observed in early childhood or later in adulthood. Usher syndrome is characterised by progressive vision loss and hearing impairment. Another disorder, retinitis pigmentosa, refers to a range of diseases causing a slow but progressive vision loss and are characterised by such symptoms as loss of peripheral vision and night blindness.
The size of genetic ophthalmology disorders pipelines ranges from 6 products in usher syndrome to 54 in retinitis pigmentosa. Today, gene therapy is the most common type of therapy used to treat genetic ophthalmology disorders, it aims at repairing the defective gene to correct a patient’s phenotype. Another existing treatment option is small molecules, they usually target the causative gene within each disease, however there are exceptions.
Cutting-edge discounted report “Genetic Ophthalmology Disorders Drug Development Pipeline Review, 2017” created by GBI Research presents access to an in-depth overview of genetic ophthalmology disorders pipeline landscape as well as uncovers reliable data on the therapeutics under development for each indication and reviews the leading players engaged in therapeutic research and development. This topical study discusses prevailing trends and emerging opportunities, touches upon the recent developments and product launches, identifies the main challenges and threats, and also gives a future outlook.
Visit GBI Research page to find a full collection of the publisher’s research reports.